Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. Voprosy onkologii, v. 67, n. 5, p. 665–674, 29 Oct.2021.